NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
Clinical Trials
13 trialsNCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT05048901 2024-07-05
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan
Phase 1/2 Recruiting
NCT05701241 2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4 Recruiting
NCT02859064 2023-12-05
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT00842348 2022-10-12
NET729
Ipsen
Phase 3 Completed
NCT04427787 2021-09-05
LOLA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02823691 2021-06-07
MetNET-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase EARLY_PHASE1 Unknown
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT00326469 2020-11-05
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
Ipsen
Phase 2 Completed
NCT02698410 2020-10-01
ATLANT
Ipsen
Phase 2 Completed
NCT03083210 2019-05-20
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
Samsung Medical Center
Phase 4 Unknown